With more than 15 million patients in Europe and in the United States, Heart failure is associated with tremendously high healthcare costs and remains the largest unmet clinical need in the cardiovascular world.

Enopace Biomedical Ltd. is developing an innovative device to treat heart failure patients.
Enopace's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload.